公开(公告)号：US20230340002A1

公开(公告)日：2023-10-26

申请号：US18044384

申请日：2021-09-09

Applicant: Stichting Katholieke Universiteit

Inventor： Johan Franciscus Adrianus Pijnenborg ,  Thomas Jan Boltje ,  Emiel Rossing

IPC: C07H11/04

CPC classification number: C07H11/04

Abstract: The present invention relates to a new class of compounds based on a hexose featuring at least two 6-fluorides. The class is useful as inhibitors of 4,6-dehydratase enzymes. Such inhibitors are suitable for use as a medicament, for example for treating, preventing, or delaying cancer, tumor metastasis, inflammation, infections, or genetic disorders.

公开(公告)号：US11236333B2

公开(公告)日：2022-02-01

申请号：US16465405

申请日：2017-12-13

Applicant: STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： Robert Wilhelmus Johanna Collin ,  Alejandro Garanto Iglesias ,  Franciscus Peter Maria Cremers ,  Silvia Albert

IPC: C07H21/04 ,  C12N15/113 ,  A61K9/00

Abstract: The present invention relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Stargardt disease.

公开(公告)号：US11053349B2

公开(公告)日：2021-07-06

申请号：US16466366

申请日：2017-12-05

Applicant: STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： Paul Kouwer ,  Alan Edward Rowan ,  Daniël Schoenmakers

IPC: C08G61/04 ,  A61L27/52 ,  C08G65/333 ,  C12N5/00

Abstract: A polymer hydrogel having a polymer formed by the crosslinking reaction of a polymeric unit A according to formula (I), with a crosslinking unit B according to formula (II) and water, wherein n=100-10,000, preferable 250-2500, more preferable 500-1500; m=independently 2-10, preferably 3 or 4; FG is a functional moiety that can be covalently coupled to the complementary functional moiety F1 or F2 of the crosslinking unit (B); k=0.01-0.05; h=0, 1 or 2; the spacer is an organic moiety, having a main chain comprising at least two functional moieties F1 and F2, wherein the length of the crosslinker in the extended conformation as determined by molecular modeling (including spacer and functional groups F1 and F2) is between 2.5 and 12 nm, or wherein the length is between 20 and 80 atoms.

公开(公告)号：US11035860B2

公开(公告)日：2021-06-15

申请号：US15528322

申请日：2015-11-18

Applicant: Stichting Katholieke Universiteit ,  Stichting VU-Vumc

Inventor： Anna Catharina Navis ,  Wilhelmus Petrus Johannes Leenders ,  Thomas Würdinger

IPC: C12Q1/68 ,  G01N33/574 ,  C12Q1/6886 ,  C07K14/71 ,  C12Q1/6883 ,  G01N33/74 ,  A61K39/00 ,  C07K16/28

Abstract: The present invention relates to the fields of medicine and molecular diagnostics. In particular, it relates to a novel method for the treatment, prevention and/or delay of cancer and to a diagnostic method involving detection of a novel auto-active and intracellular mutant of MET.

公开(公告)号：US20210107931A1

公开(公告)日：2021-04-15

申请号：US16965023

申请日：2019-01-29

Applicant: Stichting Katholieke Universiteit

Inventor： Thomas Jan Boltje ,  Torben Heise ,  Johan Franciscus Adrianus Pijnenborg ,  Christian Büll ,  Gosse Jan Adema

IPC: C07H13/12 ,  C07H13/04

Abstract: The present invention relates to a new class of sialyltransferase inhibitors. The class features a carbamate or similar moiety on the amine of a neuraminic acid derivative. Such inhibitors are suitable for use as a medicament, for example for treating, preventing, or delaying bacterial infection, viral infection, cancer, a disorder of sialic acid metabolism, or an autoimmune disease.

公开(公告)号：US10752957B2

公开(公告)日：2020-08-25

申请号：US15924040

申请日：2018-03-16

Applicant: Stichting Katholieke Universiteit, The University Medical Centre Nijmegen

Inventor： Daphne Hessels ,  Gerald Verhaegh ,  Jack A. Schalken ,  J. Alfred Witjes

IPC: C12Q1/68 ,  G01N33/574 ,  C12Q1/6886

Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.

公开(公告)号：US20200261591A1

公开(公告)日：2020-08-20

申请号：US16862570

申请日：2020-04-30

Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ,  STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： WILLEM MULDER ,  JORDI OCHANDO ,  ZAHI FAYAD ,  MIHAI NETEA ,  LEO JOOSTEN

IPC: A61K47/64 ,  A61K47/54 ,  A61K39/39 ,  A61K45/06

Abstract: The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.

公开(公告)号：US20200255832A1

公开(公告)日：2020-08-13

申请号：US16842157

申请日：2020-04-07

Applicant: STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： Robert Wilhelmus Johanna Collin ,  Franciscus Peter Maria Cremers ,  Antonia Ingrid Den Hollander

IPC: C12N15/113

Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.

公开(公告)号：US20200181564A1

公开(公告)日：2020-06-11

申请号：US16607824

申请日：2018-04-23

Applicant: STICHTING KATHOLIEKE UNIVERSITEIT

Inventor： Paul KOUWER ,  Alan ROWAN ,  Maarten JASPERS ,  Paula DE ALMEIDA

IPC: C12N5/00

Abstract: A double network hydrogel including a polymer (A) having a persistence length between 10 and 1000 nm; a flexible polymer (B), wherein the persistence length is measured according to single molecule force microscopy measurement, wherein polymer (B) has an extended coil conformation at a first condition and a collapsed globular conformation at a second condition. Polymer (A) preferably is a polyisocyanate, while polymer (B) is a crosslinked flexible polymer like for example PNIPAM. A method for making a double network hydrogel.

公开(公告)号：US10465230B2

公开(公告)日：2019-11-05

申请号：US15845562

申请日：2017-12-18

Applicant: Stichting Katholieke Universiteit

Inventor： Waander Laurens Van Heerde ,  Richard Hendrik Blaauw

IPC: C12Q1/37 ,  C12Q1/56 ,  C12Q1/66

Abstract: The present invention relates to a method for in vitro determining generation of a haemostasis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.